You are here: Home » Companies » News
Business Standard

Teva pharma to invest Rs 4,000 cr in India

P B Jayakumar  |  Mumbai 

Israel's Teva Pharmaceutical Industries, the world's largest manufacturer of copycat patented drugs (generics), plans to invest over $1 billion in India to acquire Indian drug and set up greenfield manufacturing facilities.
The investment is planned for the next 24 months. Around $250-$300 million will be utilised for manufacturing facilities and the rest to fund acquisitions in India.
A few weeks ago, Teva had acquired over 100 acres of land near Gwalior, Madhya Pradesh, to set up active pharmaceutical ingredient (API) manufacturing facilities that will match the production capacity of domestic generic majors such as Ranbaxy, Cipla, Dr Reddy's, Sun Pharma and Wockhardt, sources told Business Standard.
Sources said Teva would start civil works at the site after it obtains necessary government clearances.
"Teva considers India an interesting geographical region and is looking to broaden its activities in the country," Shir Altay, a company spokesperson said in an e-mail.
Teva is also likely to integrate Regent Drugs, which it acquired from JK Industries in 2003, with its API business (TAPI).
Regent Drugs, now a 100 per cent subsidiary of Teva, manufactures some APIs that Teva requires for its global business. The company also sources APIs from many Indian V K Batra, managing director, Regent Drugs, declined comment.
Teva has an Indian arm, Teva India, and a research and development centre in New Delhi which it started a couple of years ago.
Merchant banking sources said Teva has been aiming at a major acquisition in India for the past three years, but no deal has been struck yet, perhaps due to high valuations.
Targets include such drug majors as Cipla, Aurobindo, Matrix and Orchid, as well as Saraca Laboratories of Hyderabad.
India is an interesting geography not just for Teva, but for several global drug majors, which are attracted by the huge talent pool, scientific skills and cheap labour that has enabled Indian make drugs at about a third of the cost in the West.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, January 10 2008. 00:00 IST